文献类型：期刊文献

英文题名：Does the use of pulsed-xenon ultraviolet light reduce the risk of healthcare-associated infections?: An updated systematic review and meta-analysis

作者：Ma, Lejuan[1];Yan, Chungen[2];Huang, Yan[3];Lv, Jvmei[4];Liu, Siyan[5]

机构：[1]Shaoxing Univ, Affiliated Hosp, Sch Hlth Off, Shaoxing 312000, Zhejiang Provin, Peoples R China;[2]Shaoxing Univ, Gastroenterol Dept, Affiliated Hosp, Shaoxing 312000, Zhejiang Provin, Peoples R China;[3]Shaoxing Univ, Dept Infect Control, Affiliated Hosp, Shaoxing 312000, Zhejiang Provin, Peoples R China;[4]Shaoxing Univ, Affiliated Hosp, Intens Care Unit, Shaoxing 312000, Zhejiang Provin, Peoples R China;[5]Shaoxing Univ, Affiliated Hosp, Dept Stomatol, 575 Pingjiang Rd, Shaoxing 312020, Zhejiang Provin, Peoples R China

年份：2025

卷号：31

期号：7

外文期刊名：JOURNAL OF INFECTION AND CHEMOTHERAPY

收录：SCI-EXPANDED(收录号：WOS:001496449500001)、、Scopus(收录号：2-s2.0-105005112414)、WOS

语种：英文

外文关键词：Disinfection; Nosocomial infection; Ultra-violet light; No-touch disinfection

外文摘要：Objective: The present review was conducted to assess the ability of the pulsed-xenon ultra-violet system (PX-UVL) to reduce healthcare-associated infections (HAI). Methods: All types of studies available on PubMed, Embase, Scopus, and Web of Science databases assessing the risk of any HAI with the use of PX-UVL and published up to 25 February 2025 were included. Data on C. difficile infection (CDI), Methicillin-resistant Staphylococcus aureus (MRSA) infection, Vancomycin-resistant enterococci (VRE) infections, and Acinetobacter baumannii infections (ABI) was pooled. Results: Fourteen studies were included. Most studies had a pre-post study design while two were controlled trials. Meta-analysis showed a statistically significant reduction in the risk of CDI with PX-UVL (RR: 0.76 95 % CI: 0.59, 0.97 I2 = 72 %). However, results were significant only for pre-post studies (RR: 0.75 95 % CI: 0.57, 0.98 I2 = 73 %) but not for controlled trials (RR: 0.70 95 % CI: 0.25, 1.96 I2 = 72 %). The results were also not stable on sensitivity analysis. Meta-analysis also showed a tendency of reduction of MRSA infections but the effect size was statistically non-significant (RR: 0.80 95 % CI: 0.62, 1.02 I2 = 65 %). Pooled analysis demonstrated no significant impact of PX-UVL in reducing the risk of VRE infections (RR: 0.83 95 % CI: 0.66, 1.04 I2 = 54 %) or ABI (RR: 0.64 95 % CI: 0.21, 1.90 I2 = 96 %). Subgroup analysis based on study design showed that the risk of VRE infection did not change in both pre-post studies and controlled trials. Conclusions: Current evidence from variable study designs suggests that PX-UVL may have limited efficacy in reducing HAI. Further high-quality randomized controlled trials will provide quality evidence.